US-made capability Chartwell operates cGMP compliant facilities in New York with a long track record of in-house manufacturing, packaging, analytical services and supply chain support, positioning them to be a reliable partner for domestic production and domestic sourcing needs.

Large ANDA portfolio With over 1,100 Orange Book listings and around 700 commercialized NDCs, Chartwell presents opportunities to expand brand and generic product collaborations, regulatory support, and scale-up for existing or new therapeutic areas.

Expansion ready Significant plant expansions, acquisitions, and new dosage forms and technologies indicate capacity to absorb new lines, form partnerships around unit dose liquids and upcoming semi-solids, and support rapid onboarding for clients.

TAA and BAA compliant Manufacturing capabilities that meet Trade Act and Buy American Act requirements open doors for government and defense-related programs, as well as clients prioritizing domestic sourcing and regulatory alignment.

Growth and partnerships Recent acquisitions and a revenue footprint in the $50M–$100M range, combined with strong leadership and technical staff, suggest opportunities for collaboration on complex fill/finish, formulation development, clinical supplies, and scalable commercial production for new or existing products.